Do Patients With Inflammatory Bowel Disease Benefit from an Enhanced Recovery Pathway?

Related Articles Do Patients With Inflammatory Bowel Disease Benefit from an Enhanced Recovery Pathway? Inflamm Bowel Dis. 2019 Aug 02;: Authors: Liska D, Bora Cengiz T, Novello M, Aiello A, Stocchi L, Hull TL, Steele SR, Delaney CP, Holubar SD Abstract BACKGROUND: Enhanced recovery pathways (ERPs) have been shown to reduce length of stay (LOS), complications, and costs after colorectal surgery; yet, little data exists regarding patients with inflammatory bowel disease (IBD). We hypothesized that implementation of ERP for IBD patients is associated with shorter LOS and improved economic outcomes.…

Read More

A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis.

Related Articles A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis. Inflamm Bowel Dis. 2019 Aug 02;: Authors: Dreesen E, Kantasiripitak W, Detrez I, Stefanović S, Vermeire S, Ferrante M, Bouillon T, Drobne D, Gils A Abstract BACKGROUND: Unlike other anti-tumor necrosis factor alpha antibodies, golimumab does not deliver on its promise of effectiveness for treating patients with ulcerative colitis. We investigated the value of therapeutic drug monitoring for optimizing golimumab therapy. METHODS: We analyzed the golimumab pharmacokinetics data of 56 patients…

Read More

A Case Where Administration of Ustekinumab Maintained the Intestinal Patency After Balloon Dilation for Small Intestinal Stenosis Caused by Crohn’s Disease.

A Case Where Administration of Ustekinumab Maintained the Intestinal Patency After Balloon Dilation for Small Intestinal Stenosis Caused by Crohn’s Disease. Inflamm Bowel Dis. 2019 Aug 02;: Authors: Murate K, Nakamura M, Fujishiro M PMID: 31374114 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31374114?dopt=Abstract

Read More

A Population-Based Study of Combination vs Monotherapy of Anti-TNF in Persons With IBD.

A Population-Based Study of Combination vs Monotherapy of Anti-TNF in Persons With IBD. Inflamm Bowel Dis. 2019 Jul 24;: Authors: Elias ED, Targownik LE, Singh H, Bernstein CN Abstract BACKGROUND: Few data exist about the utilization of combination therapy (anti-tumor necrosis factor [anti-TNF] plus immunosuppressives) in clinical practice. We assessed the prevalence and predictors of combination therapy use vs anti-TNF monotherapy in inflammatory bowel disease (IBD) in the Canadian province of Manitoba. METHODS: All 23 prescribers of anti-TNF medications for IBD in Manitoba facilitated chart review of their comprehensive lists…

Read More

Corrigendum to Predicting Risk of Postoperative Disease Recurrence in Crohn’s Disease: Patients With Indolent Crohn’s Disease Have Distinct Whole Transcriptome Profiles at the Time of First Surgery.

Corrigendum to Predicting Risk of Postoperative Disease Recurrence in Crohn’s Disease: Patients With Indolent Crohn’s Disease Have Distinct Whole Transcriptome Profiles at the Time of First Surgery. Inflamm Bowel Dis. 2019 Jul 22;: Authors: PMID: 31329224 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31329224?dopt=Abstract

Read More

Trends of Utilization of Tumor Necrosis Factor Antagonists in Children With Inflammatory Bowel Disease: A Canadian Population-Based Study.

Trends of Utilization of Tumor Necrosis Factor Antagonists in Children With Inflammatory Bowel Disease: A Canadian Population-Based Study. Inflamm Bowel Dis. 2019 Jul 19;: Authors: El-Matary W, Leung S, Tennakoon A, Benchimol EI, Bernstein CN, Targownik LE Abstract BACKGROUND: Population-based studies examining the prevalence of anti-tumor necrosis factor (anti-TNF) antagonist utilization in children and young adults with inflammatory bowel disease (IBD) are lacking. We aimed to describe the trend of anti-TNF utilization in pediatric IBD over time. METHODS: Survival analyses were performed for all patients diagnosed with IBD before age…

Read More

Opportunistic Infections Are More Prevalent in Crohn’s Disease and Ulcerative Colitis: A Large Population-Based Study.

Opportunistic Infections Are More Prevalent in Crohn’s Disease and Ulcerative Colitis: A Large Population-Based Study. Inflamm Bowel Dis. 2019 Jul 17;: Authors: Sheriff MZ, Mansoor E, Luther J, Ananthakrishnan AN, Abou Saleh M, Ho E, Briggs FBS, Dave M Abstract BACKGROUND: Opportunistic infections (OIs) are more common in patients with inflammatory bowel disease (IBD); however, there have been limited large-scale studies of OIs in IBD. We investigated the epidemiological characteristics of OI in Crohn’s disease (CD) and ulcerative colitis (UC) using a large population-based database. METHODS: Data were collected from…

Read More
<< Go Back